Optimization of Drug Delivery Systems for Intraperitoneal Therapy to Extend the Residence Time of the Chemotherapeutic Agent

Intraperitoneal (IP) chemotherapy is an effective way of treating peritoneal carcinomatosis of colorectal origin after complete cytoreduction. Although IP therapy has been already performed for many years, no standardized treatment design has been developed in terms of schedule, residence time, drug...

Full description

Saved in:
Bibliographic Details
Published in:TheScientificWorld 2013-01, Vol.2013 (2013), p.1-7
Main Authors: Vervaet, C., Remon, J. P., Ceelen, Wim P., De Smet, L.
Format: Article
Language:English
Subjects:
Abdomen
Animals
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - pharmacokinetics
Cancer therapies
Chemotherapy
Colorectal cancer
Cytotoxicity
Delayed-Action Preparations - administration & dosage
Delayed-Action Preparations - chemical synthesis
Delayed-Action Preparations - pharmacokinetics
Design standards
Drug delivery
Drug delivery systems
Drug development
Gastric cancer
Humans
Hyperthermia
Implants
Injections, Intraperitoneal - methods
Intravenous administration
Liposomes
Micelles
Microparticles
Nanocapsules - administration & dosage
Nanocapsules - chemistry
Nanoparticles
Neoplasms - drug therapy
Neoplasms - metabolism
Oncology
Peritoneum
Pharmacology
Residence time distribution
Review
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intraperitoneal (IP) chemotherapy is an effective way of treating peritoneal carcinomatosis of colorectal origin after complete cytoreduction. Although IP therapy has been already performed for many years, no standardized treatment design has been developed in terms of schedule, residence time, drug, or carrier solution. Because of the fast clearance of the conventional intravenous (IV) drug delivery systems used for IP therapy, a lot of research is performed to optimize IP drug delivery and extend the residence time of the cytotoxic agent in the peritoneal cavity. This paper reviews the recent advances made in drug delivery systems for IP chemotherapy, discussing the use of microparticles, nanoparticles, liposomes, micelles, implants, and injectable depots for IP delivery.
ISSN:2356-6140
1537-744X
DOI:10.1155/2013/720858